Needham ups Autolus target, names top pick for 2026

Group 1 - Needham raised the price target on Autolus Therapeutics (AUTL) to $11 from $10 and maintains a Buy rating on the shares [1] - Autolus is named a top pick for 2026, with impressive sales of $76 million from the launch of Aucatzyl [1] - Despite skepticism from investors regarding Autolus reaching breakeven, Needham believes the shares offer an attractive valuation and strong opportunity for value creation in 2026 [1] Group 2 - Data from the FELIX study and results from obe-cel in relapsed/refractory acute lymphoblastic leukemia indicate an expanding addressable market for Autolus [1] - Needham's modeling suggests Autolus could reach breakeven by 2028 based solely on Aucatzyl sales [1] - The potential of obe-cel in lupus nephritis is currently underappreciated, which may change with clinical updates expected in the first half of 2026 [1]